Table 2.

Outcomes of ADCs treatment in urothelial carcinoma from ASCO-GU 2023

Drug	Indication	Agents	Pts	ORR (%)	OS	PFS	DOR	TRAEs	NCT	References
EV	la/mUC	EV + Pembro	76	64.5	–	–	–	Skin reactions, peripheral neuropathy	NCT03288545	[1]
		EV	73	45.2	–	–	–
	NMIBC	EV	Trials in progress						NCT05014139	[2]
SG	la/mUC	Cohort 1 SG	113	28	10.9	5.4	6.1	Neutropenia, anemia,	NCT03547973	[3]
		Cohort 2 SG	38	32	13.5	5.6	5.6	Leukopenia, fatigue		[4]
		Cohort 3 SG + Pembro	41	41	12.7	5.3	11.1	Diarrhea, febrile		[5]
		Cohort 5 SG + ZIM versus ZIM versus avelumab	Trials in progress					Neutropenia		[6]
		Cohort 6 SG versus SG + CPI versus carboplatin/GEM	Trials in progress							[7]
	mUC	SG + IPI + NIVO	6	66.6	–	8.8	9.2	Anemia, neutropenia, Pruritus, fatigue, Diarrhea, lymphopenia, arthralgia	NCT04863885	[8]
RC48	HER2 + laUC/mUC		Trials in progress						NCT04879329	[10]

ADCs Antibody–drug conjugates, CPI Checkpoint inhibitor, DOR Duration of response, EV Enfortumab vedotin, GEM Gemcitabine, HER2 Human epidermal growth factor receptor 2, IPI Ipilimumab, la/mUC Locally advanced/metastatic urothelial carcinoma, NIVO Nivolumab, NMIBC Non muscle-invasive bladder cancer, ORRObjective response rate, OS Overall survival, Pembro Pembrolizumab, PFS Progression-free survival, Pts Patients, RC48 Disitamab vedotin, SG Sacituzumab govitecan, TRAEs Treatment-related adverse events, ZIM Zimberelimab